Meeting
2016 ASCO Annual Meeting
Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?
Authors
Thierry Landre
Hôpital Rene Muret, HUPSSD, UCOG 93 (APHP), Sevran, France
Thierry Landre , Cherifa Taleb , Patrick Nicolas , Gaetan Des Guetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3070)
DOI
10.1200/JCO.2016.34.15_suppl.3070
Abstract #
3070
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC).
First Author: Ruchit Shah
Poster
2016 ASCO Annual Meeting
Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).
First Author: Jonathan Wade Goldman
Poster
2016 Genitourinary Cancers Symposium
CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
First Author: Robert J. Motzer
Poster
2023 ASCO Genitourinary Cancers Symposium
Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.
First Author: Saby George